Recently, a tri-modular CAR-T construct, CART-EGFR-IL13Rα2-dnTGFβRII has been developed to overcome the immunosuppressive GBM microenvironment by mitigating TGF-β-mediated suppression. The gene discussed is TGFB1; the disease is glioblastoma.